IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
Company/Organization Date Area of
Collaboration
Terms of Agreement
Compugen 2005 Systems biology Pilot research project in the field of
systems biology. Compugen will generate
information about biological interaction
network through the development of a
proprietary platform for research and
analysis of microarray and other biological
data. Novartis will obtain sole rights to the
specific results of the project, and
Compugen will retain all rights to the
research and discovery systems developed
through the collaboration.
ESBATech 2005 Drug discovery Collaboration on the discovery of receptor
tyrosine kinase inhibitors using
ESBATech’s cellular HTS technology for
inhibitor identification. ESBATech will
receive up-front and milestone payments
and research funding.
Biotech (Thailand’s
National Center for
Genetic Engineering and
Biotechnology)
2005 Natural products Agreement with the Thai government to
develop new medicines based on natural
herbs found in Thailand. Biotech will
receive technology transfer and financial
contributions.
Avanir 2005 Inflammation drugs Global research, development and
commercialization agreement to develop
orally active small molecules therapeutics
targeting macrophage migration inhibitory
factor (MIF) as potential treatments for
inflammatory diseases. Avanir will receive
over $200m in combined upfront and
milestone payments, plus royalties and
funding of up to $2.5m per year for up to
four years.
Infinity 2005 Chemical drug
development
© 2009 IMS Health In cor po rated or its af fil i ates Page 135
Two-year collaborative agreement for
development of small molecules for the
potential treatment of undisclosed
indications. The molecules are to be
designed by both companies, and
synthesized using Infinity’s
diversity-oriented synthesis technology.